secwatch.observer — SEC 8-K summary
======================================

Issuer:     Insight Molecular Diagnostics Inc. (IMDX)
CIK:        0001642380
Form:       8-K
Filed at:   2022-11-09T23:59:59+00:00
Accession:  0001493152-22-031088
Event type: other
Sentiment:  neutral
Materiality: 0.15
Item codes: 5.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Oncocyte amends bylaws to allow President role independent of CEO
-----------------------------------------------------------------

- Board approved Second Amended and Restated Bylaws effective November 3, 2022.
- Amendment permits appointment of a President without requiring the CEO to also serve as President.
- Full text of amended bylaws is filed as Exhibit 3.1 to the Form 8-K.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1642380/000149315222031088/0001493152-22-031088-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1642380/000149315222031088/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-22-031088

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer